Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.

Abstract

A series of saligenin beta(2) adrenoceptor agonist antedrugs having high clearance were prepared by reacting a protected saligenin oxazolidinone with protected hydroxyethoxyalkoxyalkyl bromides, followed by removal of the hydroxy-protecting group, alkylation, and final deprotection. The compounds were screened for beta(2), beta(1), and beta(3) agonist activity in CHO cells. The onset and duration of action in vitro of selected compounds were assessed on isolated superfused guinea pig trachea. Compound 13f had high potency, selectivity, fast onset, and long duration of action in vitro and was found to have long duration in vivo, low oral bioavailability in the rat, and to be rapidly metabolized. Crystalline salts of 13f (vilanterol) were identified that had suitable properties for inhaled administration. A proposed binding mode for 13f to the beta(2)-receptor is presented.

DOI: 10.1021/jm100326d
0102020102011201220132014201520162017
Citations per Year

51 Citations

Semantic Scholar estimates that this publication has 51 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Procopiou2010SynthesisAS, title={Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.}, author={Panayiotis A. Procopiou and Victoria J.M. Barrett and Nicola J Bevan and Keith Biggadike and Philip C Box and Peter R Butchers and Diane M. Coe and Richard Conroy and Amanda J Emmons and Alison J Ford and Duncan S Holmes and Helen Horsley and Fern Kerr and Anne-Marie Li-Kwai-Cheung and Brian E Looker and Inderjit S Mann and Iain M. McLay and Valerie S. Morrison and Peter J Mutch and Claire El Smith and Paula Tomlin}, journal={Journal of medicinal chemistry}, year={2010}, volume={53 11}, pages={4522-30} }